Compare Abbott Laboratories (ABT) vs Check Point Software Technologies Ltd (CHKP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Check Point Software Technologies Ltd — how do they compare? Abbott Laboratories trades at $94.9 (market cap $166.94B), while Check Point Software Technologies Ltd trades at $136.86 (market cap $14.43B). The key difference: Abbott Laboratories is far larger — about 11.6× Check Point Software Technologies Ltd's market cap, and Abbott Laboratories pays a 2.63% dividend while Check Point Software Technologies Ltd pays none. Which is the better fit depends on your goals.
| ABT | CHKP | |
|---|---|---|
Market Cap | $166.94B | $14.43B |
Sector | Health | Technology |
52-Week High | $136.62 | $231.23 |
52-Week Low | $82.57 | $112.47 |
Enterprise Value | $193.69B | $13.64B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
CHKP trades at $138.87, up 1.68% today, with a bullish technical outlook supported by moving averages and strong support at $136. The company demonstrates robust fundamentals with a 38.37% net income margin, consistent earnings beats, and strategic AI partnerships enhancing its cybersecurity offerings. Recent news highlights ESG reporting and cloud security expansions.
Outlook remains positive with a consensus price target of $148.73, though risks include insider sales and legal investigations. The stock offers growth potential from AI integration but faces competitive and regulatory headwinds that warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Check Point Software Technologies Ltd
Check Point is a global leader in cybersecurity solutions. It provides comprehensive protection against advanced cyber threats for corporate networks, cloud environments, mobile devices, and critical infrastructure.
Read more on CHKP →
